Protein S100B

Tumour Marker: Protein S100B in serum or CSF measured by a chemiluminescent method on the Liaison analyser (DiaSorin).
Clinical details: 
Protein S100B is a member of a family of calcium binding proteins. S100B is present in astrocytes and glial cells in the brain and also in melanocytes. Protein S100B is currently being used in monitoring patients with malignant melanoma. Whilst the diagnosis of melanoma uses a combination of clinical and histological features, detection of metastases can be more difficult. A value greater than 0.2 µg/L is indicative of advanced disease (Stages 3 and 4) with a Positive Predictive Value of approximately 90%. Rising values can be seen 1-2 months in advance of clinical features of metastatic disease. The plasma concentration of S100B has been shown to be related to tumour burden and gives an early indication of successful response to chemotherapy. Values that fail to fall after one month of chemotherapy indicate the tumour is insensitive to the particular chemotherapy regime.

S100B is also a biochemical marker of brain injury and and a number of studies have been carried out to investigate its role in assessing and monitoring of closed head injuries and stokes.
Reference range: 

The normal range for serum S100B is 0.02-0.2 µg/L

Synonyms or keywords: 
S100B, s100b, s100
Sample type and Volume required: 
Serum (250 µL). Should be separated from red cells within 2-4 hours.
Turnaround time: 
Within 7 working days.
Storage and transport: 
Stable at 4°C for up to two days. Send by overnight first class post.
Reference Biochemistry Department at King's College Hospital
020 3299 4107
King's College Hospital
Denmark Hill
London SE5 9RS
Immunochemistry Laboratory at King's College Hospital
020 3299 4130
King's College Hospital
Denmark Hill
London SE5 9RS
For clinical advice or interpretation of results, please contact the laboratory in the first instance.

Print as a PDF

Last updated: 19/08/2015